Related Experiment Video
Updated: Jul 10, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Genitourinary cancers updates: highlights from ASCO 2023
Qian Qin1, Hollie Sheffield1, Sean M Taasan1
1Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Abstract:
Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP inhibitors for prostate cancer, antibody drug conjugates and fibroblast growth factor receptor inhibitors for urothelial cancer, and HIF2a inhibitors for renal cell carcinoma. Novel agents such as bispecific antibodies, chimeric antigen receptor T-cells, and radiopharmaceuticals are currently in early phase development and also have high potential impact for the GU cancer landscape. With more treatment options, the field will need to define best treatment sequencing to optimize outcomes for each patient.
Insights
Recent advances in immunotherapy and targeted therapy offer new hope for genitourinary (GU) cancers. ASCO 2023 highlighted novel agents and the need for optimal treatment sequencing in GU malignancies.
Area of Science:
- Genitourinary (GU) oncology
- Cancer therapeutics
- Clinical trial advancements
Background:
- Genitourinary (GU) malignancies represent a significant area of cancer research.
- Recent years have seen substantial progress in immunotherapy and targeted therapy for GU cancers.
- Improved clinical outcomes and expanded treatment options are transforming patient care.
Related Concept Videos
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Survival Analysis

